Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease (original) (raw)
Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial
Limas Kupcinskas, Ivan Bunganič, Daniel Tuculanu, Roland Greinwald
Journal of Crohn's and Colitis, 2014
View PDFchevron_right
Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial
William Sandborn
View PDFchevron_right
Systematic review: the effectiveness of budesonide therapy for Crohn's disease
William Sandborn
View PDFchevron_right
Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis
Bengt-ake Bengtsson
Alimentary Pharmacology & Therapeutics, 2009
View PDFchevron_right
Budesonide for maintenance of remission in Crohnʼs disease: A systematic review and meta-analysis for the Cochrane Collaboration
Eric I Benchimol
Inflammatory Bowel Diseases, 2008
View PDFchevron_right
Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: A multicentre, double-blind, randomized, parallel-group Phase II study
Satoshi Motoya
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Budesonide in the treatment of Crohn's disease: a meta-analysis
Maurizio Koch, Roberto Luchetti
Alimentary Pharmacology and Therapeutics, 2000
View PDFchevron_right
Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohnʼs disease: A randomized placebo-controlled trial
Roland Greinwald
Inflammatory Bowel Diseases, 2009
View PDFchevron_right
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life
Derek Jewell
The American journal of gastroenterology, 2002
View PDFchevron_right
Oral budesonide as maintenance treatment for Crohn's disease: A placebo- controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group
Frances Martin
Gastroenterology, 1996
View PDFchevron_right
Medical treatment of moderate to severe Crohn's disease
C. Prantera, M. Scribano
Alimentary Pharmacology and Therapeutics, 2003
View PDFchevron_right
Safety and effectiveness of long-term budesonide treatment in maintaining remission in patients with mild-to-moderate Crohnʼs disease
Antonio Tursi
Inflammatory Bowel Diseases, 2007
View PDFchevron_right
Budesonide Is More Effective Than Mesalamine or Placebo in Short-term Treatment of Collagenous Colitis
Limas Kupcinskas, Michael Vieth
Gastroenterology, 2014
View PDFchevron_right
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial
Ewa Małecka-Panas, Libor Gabalec
View PDFchevron_right
Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial
Eric Drouin
Gastroenterology, 2001
View PDFchevron_right
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Kaija-leena Kolho
Journal of Crohn's and Colitis, 2010
View PDFchevron_right
Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease
Martin Bergstrand
Alimentary Pharmacology and Therapeutics, 2003
View PDFchevron_right
Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules
Alan Lobo
Alimentary Pharmacology and Therapeutics, 2001
View PDFchevron_right
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
Cosimo Prantera
Gastroenterology, 1999
View PDFchevron_right
Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis
Per Hellström
Gastroenterology
View PDFchevron_right
Budesonide for ulcerative colitis
Amado Salvador Peña
Falk Symposium
View PDFchevron_right
Oral budesonide for induction of remission in ulcerative colitis
Hillary Steinhart
Reviews, 1996
View PDFchevron_right
Medical treatment of active Crohn's disease
C. Prantera, M. Scribano
Alimentary Pharmacology and Therapeutics, 2002
View PDFchevron_right
Budesonide Is Effective in Treating Lymphocytic Colitis: A Randomized Double-Blind Placebo-Controlled Study
Roland Greinwald
Gastroenterology, 2009
View PDFchevron_right
Evidence-based treatment algorithm for mild to moderate Crohn's disease
William Sandborn
The American journal of gastroenterology, 2003
View PDFchevron_right
Budesonide Use and Hospitalization Rate in Crohn's Disease: Results From a Cohort at a Tertiary Care IBD Referral Center
Fenglong Xie
Journal of clinical medicine research, 2016
View PDFchevron_right
Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
Pilar Nos
Clinical and Experimental Gastroenterology, 2014
View PDFchevron_right
Evaluation of oral budesonide in the treatment of active distal ulcerative colitis
Roland Greinwald
Drugs of today (Barcelona, Spain : 1998), 2004
View PDFchevron_right
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
Michael Huang
Gastroenterology, 2012
View PDFchevron_right